RxDoctor Payments Data
★ My doctorsLook up a doctor →

Guldeniz Doganay

Cardiovascular Disease · Brooklyn, NYNPI 1114023918

Payments from drug & device makers

$1,189in general payments, 2019–2025

Across 63 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$204
  • Bayer$142
  • Merck$103
  • Pfizer$100
  • Esperion Therapeutics, Inc.$66
  • Novo Nordisk$65
  • plus $508 from 14 others

What the payments were for

  • Food & beverage$1,189100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amarin Pharma, Inc.12$204
Bayer6$142
Merck6$103
Pfizer6$100
Esperion Therapeutics, Inc.3$66
Novo Nordisk3$65
Abbott3$64
Sanofi-aventis U.S. LLC3$55
Bardy Diagnostics, Inc.2$52
Johnson & Johnson3$48
Novartis2$47
Boehringer Ingelheim2$43
AstraZeneca2$34
Genentech USA, Inc.2$32
Lilly USA, LLC2$29
E.r. Squibb & Sons, L.L.C.2$29
Amgen1$23
Sanofi Pasteur Inc.1$18
Edwards Lifesciences1$17
Kowa Pharmaceuticals America, Inc.1$16

How this compares

$1,189 in reported general payments places this provider in the 40th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York →

Other cardiovascular disease in Brooklyn

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →